family with sequence similarity 138 member BGenealiases: F379 · bA395L14.6
Q-omics provides the consensus-scored FAM138B profile across patient tissues and cancer cell-line models. FAM138B expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FAM138B is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, FAM138B RNA expression shows 8,847 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, BLCA, and TGCT as cancer lineages where FAM138B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM138B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM138B survival associations across molecular data types. FAM138B RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM138B RNA expression–survival associations across cancer types. High FAM138B expression shows unfavorable associations in COAD, ACC, LUSC, BRCA and LGG, but favorable associations in MESO. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for FAM138B RNA expression.
This table summarizes FAM138B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM138B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM138B shows lower tumor expression in BLCA, LUSC, UCEC, LUAD, BRCA and COAD. The BLCA box plot shows higher FAM138B RNA expression in normal versus tumor tissue (log2 FC = −0.494, t-test p < 0.001).
This table shows molecular features associated with FAM138B in patient tissues and cancer cell lines. In patient samples, FAM138B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
